Boston Scientific (BSX +0.3%) is rumored to be putting its CroFab (Crotalidae Polyvalent Immune Fab [Ovine]), a sheep-derived antivenin for the treatment of pit viper bites (includes rattlesnakes, copperheads, water moccasins), business up for sale.

The company acquired the product via its acquisition of BTG plc about a year ago. It is part of a three-drug portfolio that BSX reports as "Specialty Pharmaceuticals." In Q1, the unit generated $41M in sales ($37M in U.S.). CroFab's contribution was not disclosed.

READ FULL ARTICLE HERE